Certara (NASDAQ:CERT – Get Free Report) and PLAYSTUDIOS (NASDAQ:MYPS – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.
Insider and Institutional Ownership
74.0% of Certara shares are owned by institutional investors. Comparatively, 37.5% of PLAYSTUDIOS shares are owned by institutional investors. 2.4% of Certara shares are owned by insiders. Comparatively, 14.3% of PLAYSTUDIOS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Certara and PLAYSTUDIOS”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Certara | $372.80 million | 5.83 | -$55.36 million | ($0.20) | -67.45 |
PLAYSTUDIOS | $310.89 million | 0.75 | -$19.39 million | ($0.19) | -9.87 |
Volatility and Risk
Certara has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, PLAYSTUDIOS has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
Profitability
This table compares Certara and PLAYSTUDIOS’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Certara | -8.34% | 3.43% | 2.33% |
PLAYSTUDIOS | -8.75% | -9.15% | -7.29% |
Analyst Ratings
This is a summary of recent ratings for Certara and PLAYSTUDIOS, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Certara | 0 | 6 | 2 | 0 | 2.25 |
PLAYSTUDIOS | 1 | 2 | 2 | 0 | 2.20 |
Certara presently has a consensus price target of $15.92, indicating a potential upside of 17.99%. PLAYSTUDIOS has a consensus price target of $3.63, indicating a potential upside of 93.23%. Given PLAYSTUDIOS’s higher possible upside, analysts clearly believe PLAYSTUDIOS is more favorable than Certara.
Summary
Certara beats PLAYSTUDIOS on 8 of the 13 factors compared between the two stocks.
About Certara
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
About PLAYSTUDIOS
PLAYSTUDIOS, Inc. develops and publishes free-to-play casual games for mobile and social platforms in the United States and internationally. The company's game portfolio includes a diverse range of titles comprising social casino, card, puzzle, and adventure games. It also offers POP! Slots, myVEGAS Slots, my KONAMI Slots, MGM Slots Live, myVEGAS Blackjack, myVEGAS Bingo, Tetris, Solitaire, Spider Solitaire, Jumbline 2, Sudoku, and Mahjong games. PLAYSTUDIOS, Inc. is headquartered in Las Vegas, Nevada.
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.